Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 11.35MM shares of EXACT Sciences Corporation (EXAS). This represents 6.4% of the company.
In their previous filing dated February 4, 2022 they reported 9.50MM shares and 5.50% of the company, an increase in shares of 19.55% and an increase in total ownership of 0.90% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 6.91% Downside
As of February 7, 2023, the average one-year price target for EXACT Sciences is $62.50. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents a decrease of 6.91% from its latest reported closing price of $67.14.
The projected annual revenue for EXACT Sciences is $2,322MM, an increase of 15.80%. The projected annual EPS is $-2.69.
Fund Sentiment
There are 971 funds or institutions reporting positions in EXACT Sciences. This is an increase of 18 owner(s) or 1.89%.
Average portfolio weight of all funds dedicated to US:EXAS is 0.1824%, a decrease of 3.8096%. Total shares owned by institutions decreased in the last three months by 1.28% to 204,472K shares.
What are large shareholders doing?
ARK Investment Management holds 16,040,490 shares representing 9.03% ownership of the company. In it's prior filing, the firm reported owning 17,561,702 shares, representing a decrease of 9.48%. The firm increased its portfolio allocation in EXAS by 73.05% over the last quarter.
Wellington Management Group Llp holds 11,227,634 shares representing 6.32% ownership of the company. In it's prior filing, the firm reported owning 10,083,742 shares, representing an increase of 10.19%. The firm decreased its portfolio allocation in EXAS by 2.87% over the last quarter.
ARKK - ARK Innovation ETF holds 11,225,550 shares representing 6.32% ownership of the company. In it's prior filing, the firm reported owning 10,053,642 shares, representing an increase of 10.44%. The firm increased its portfolio allocation in EXAS by 4.77% over the last quarter.
Nikko Asset Management Americas holds 6,028,620 shares representing 3.39% ownership of the company. In it's prior filing, the firm reported owning 5,320,404 shares, representing an increase of 11.75%. The firm increased its portfolio allocation in EXAS by 1.72% over the last quarter.
Price T Rowe Associates holds 5,814,177 shares representing 3.27% ownership of the company. In it's prior filing, the firm reported owning 15,422,384 shares, representing a decrease of 165.25%. The firm decreased its portfolio allocation in EXAS by 59.68% over the last quarter.
Exact Sciences Background Information
(This description is provided by the company.)
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
